The Boston Globe reports on Cubist's move to purchase biotech company

The Boston Globe reports that Cubist Pharmaceuticals Inc., whose chief executive and president is Michael Bonney ’80, will spend up to $402.5 million to buy Calixa Therapeutics of San Diego, Calif., a company that is developing an antibiotic to fight so-called superbugs. “It’s right in our sweet spot, right in our strike zone,’’ Bonney told the paper. Cubist also markets an antibiotic, Cubicin, to battle infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) bacteria. View story from The Boston Globe, Dec. 14, 2009.

Comments are closed.